Last reviewed · How we verify

NCT07222813

Evaluation of Liver Stiffness Performance, by FibroScan®, to Detect Elevated Central Venous Pressure (CVP)

Not yet recruiting NA Last updated 30 October 2025
What this trial tests

NA trial testing FibroScan in Heart Failure in 149 participants. Not yet recruiting.

Timeline
15 January 2026
Primary endpoint
31 December 2026
15 January 2027

Quick facts

Lead sponsorEchosens
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment149
Start date15 January 2026
Primary completion31 December 2026
Estimated completion15 January 2027
Sites7 locations across France, United States, Germany, Poland

Drugs / interventions tested

Conditions studied

Sponsor

Echosens — full company profile →

Who can join

18 and older, any sex, with Heart Failure or Heart Failure - NYHA II - IV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pivotal, global, prospective, cross-sectional, multicentric clinical investigation designed to explore a non-invasive, reliable alternative to invasive, catheter-based hemodynamic assessments, which are associated with procedural risks and limited applicability in certain participant populations.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of FibroScan

Trials testing the same drug.

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

Other Echosens trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07222813.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing